Solventum Corporation $SOLV Shares Acquired by California State Teachers Retirement System

Key Points

• California State Teachers Retirement System increased its Solventum stake by 5,434.1% in the second quarter, acquiring nearly 13 million additional shares and ending the period with a 7.78% ownership position worth approximately $1.02 billion.
• Analysts largely remain bullish: Solventum has an average “Moderate Buy” rating and a consensus price target of $92.80, with several firms recently raising targets to between $95 and $105.
• Solventum exceeded quarterly expectations, reporting $2.55 in earnings per share versus the $1.91 consensus estimate and $2.21 billion in revenue, up 2.2% year over year.

California State Teachers Retirement System increased its position in Solventum Corporation (NYSE:SOLV - Free Report) by 5,434.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 13,234,928 shares of the company's stock after purchasing an additional 12,995,776 shares during the period. California State Teachers Retirement System owned 7.78% of Solventum worth $1,021,075,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Independent Franchise Partners LLP increased its position in Solventum by 19.0% in the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company's stock valued at $1,216,785,000 after acquiring an additional 2,456,451 shares during the period. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in shares of Solventum in the second quarter valued at approximately $150,066,000. Norges Bank acquired a new position in shares of Solventum in the fourth quarter valued at approximately $147,467,000. Diamond Hill Capital Management Inc. raised its stake in shares of Solventum by 152.2% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company's stock worth $167,119,000 after purchasing an additional 1,272,921 shares during the last quarter. Finally, Boston Partners lifted its holdings in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company's stock worth $338,006,000 after purchasing an additional 959,543 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. UBS Group upped their price objective on shares of Solventum from $95.00 to $101.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Wall Street Zen raised shares of Solventum from a "hold" rating to a "buy" rating in a report on Saturday. BTIG Research raised their price objective on shares of Solventum from $91.00 to $95.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. KeyCorp lifted their price objective on Solventum from $93.00 to $102.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Finally, Piper Sandler increased their target price on Solventum from $92.00 to $105.00 and gave the stock an "overweight" rating in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Solventum currently has an average rating of "Moderate Buy" and a consensus price target of $92.80.

Solventum Trading Down 0.3%

Shares of Solventum stock opened at $87.43 on Friday. The company has a 50-day moving average of $85.15 and a two-hundred day moving average of $76.55. Solventum Corporation has a 12-month low of $62.38 and a 12-month high of $94.16. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. The stock has a market cap of $14.88 billion, a PE ratio of 10.69, a price-to-earnings-growth ratio of 1.36 and a beta of 0.61.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same quarter in the previous year, the company earned $1.69 EPS. The company's quarterly revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, research analysts anticipate that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Solventum Profile

Solventum Corporation NYSE: SOLV is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.